In a striking revelation, internal Environmental Protection Agency (EPA) records have unveiled a meeting between senior US regulators and Bayer’s CEO, Bill Anderson, where discussions centred on ongoing litigation regarding the company’s glyphosate-based herbicides, notably Roundup. This significant encounter took place on 17 June 2025, just months before the Trump administration took pivotal steps to bolster Bayer’s position in high-stakes litigation linked to allegations that its products cause cancer.
Meeting with Regulatory Officials
The meeting, which included key figures from the EPA such as Administrator Lee Zeldin and Nancy Beck, the principal deputy assistant administrator, was reportedly focused on “litigation” matters, including prospective “supreme court action.” Bayer has faced mounting lawsuits from thousands of claimants who assert that exposure to glyphosate products has led to cancer diagnoses, a claim supported by extensive research over the years.
Bayer’s strategy to mitigate the financial fallout from these lawsuits—costing the company billions in settlements—hinges on a critical legal argument: if the EPA does not mandate a cancer warning for glyphosate, Bayer should not be held liable for failing to provide one. While one appellate court has sided with this argument, many others have rejected it, including stances taken by the Biden administration’s solicitor general.
Trump Administration’s Support for Bayer
The Trump administration has shown considerable support for Bayer since the June meeting, culminating in a series of actions that favour the company’s legal arguments. A significant moment came on 1 December 2025, when D John Sauer, appointed by Trump, urged the Supreme Court to hear Bayer’s case. Following this, the court agreed to review the matter, scheduling a hearing for 27 April 2026. Compounding this, the White House invoked the Defense Production Act on 18 February 2026, ensuring the continued production of glyphosate and offering additional legal protections for manufacturers like Bayer.
This support extended further on 2 March, when Sauer submitted an amicus brief that unequivocally backed Bayer’s position, a move that has raised eyebrows among legal experts and advocacy groups alike.
Concerns Over Corporate Influence
Critics have voiced serious concerns about the implications of such meetings between high-ranking corporate executives and government officials. Nathan Donley, the environmental health science director at the Center for Biological Diversity, highlighted the troubling reality that political appointees at the EPA seem more focused on safeguarding corporate profits than protecting public health. The notion that a major pesticide company can engage privately with regulatory officials to discuss limiting liability raises significant ethical questions.
Whitney Di Bona, a consumer safety advocate, echoed these sentiments, questioning whether the voices of affected individuals—those alleging cancer due to glyphosate exposure—were afforded any similar opportunity for dialogue with the EPA. This disparity reveals a concerning trend where corporate interests may overshadow public health and safety considerations.
The Voice of Advocacy Groups
Zen Honeycutt, founder of Moms Across America, remarked on the pervasive influence of chemical companies over regulatory agencies, suggesting that such coercion is not a novel phenomenon. She pointed out that her organisation has engaged with the EPA on multiple occasions, yet has seen little action on calls to restrict harmful pesticides. The disparity in access to decision-makers highlights a systemic issue in regulatory processes that prioritises corporate dialogue over community concerns.
Why it Matters
The implications of this meeting extend far beyond corporate interests; they underscore the urgent need for transparency and accountability in regulatory frameworks that govern public health. As litigation against Bayer continues to unfold, the question remains: will the voices of those harmed by glyphosate products be heard, or will corporate influence continue to dictate the terms of safety and justice? The outcome of this battle could set a precedent that shapes the future of environmental health and corporate accountability in America.
